QL 2107
Alternative Names: QL-2107Latest Information Update: 07 Feb 2024
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Dec 2023 Qilu Pharmaceutical plans a phase I trial in Solid tumours (In volunteers, In adults, Combination therapy) in China (IV) in December 2023 (NCT06173011)
- 19 Dec 2023 Preclinical trials in Solid tumours in China (IV) prior to December 2023
- 12 Dec 2023 Phase-I clinical trials in Solid tumours (In volunteers) in China (IV) (NCT06173011)